Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download MaxCyte Announces a CRADA with US Army Medical Research
Document related concepts
Transcript
Contact: Karen Donato, PhD Executive Vice President Global Business Development & Marketing [email protected] +1-‐301-‐944-‐1700 MaxCyte Announces a CRADA with US Army Medical Research Institute of Infectious Diseases for an Exploratory Research Collaboration on Rapid Response Medical Countermeasures Gaithersburg, MD, May 17, 2016 – MaxCyte® Inc., the developer and supplier of cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-‐oncology, announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) to collaborate in the evaluation of the MaxCyte Scalable Transfection Platform for the rapid development of cell-‐based proteins such as vaccines and other treatments for medical countermeasures against infectious diseases and biological threats. “MaxCyte flow electroporation—a clinically proven, cell transfection method—enables accelerated and scalable development of recombinant proteins that could be used to respond to pandemic, biodefense, or seasonal influenza needs,” explained Dr. Karen Donato, Executive Vice President, Global Business Development and Marketing, MaxCyte. Inc. “We are honored to partner with USAMRIID in exploring ways the MaxCyte platform can be used to improve the response to emerging health threats.” About MaxCyte MaxCyte is driving the next generation of cell-‐based medicines. Its best-‐in-‐class cell modification technology is used in the discovery, development, and manufacture of small molecule, biologic, and cell-‐ based medicines. The MaxCyte GT® Flow Transfection System, the MaxCyte STX® Scalable Transfection System, and the MaxCyte VLX® Large Scale Transfection System enable the rapid development and consistent production of (co)transfected cells for cell-‐based assays, cellular therapy, genetic engineering, protein and antibody production, and rapid response vaccine development with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale. For more information, http://www.maxcyte.com. About USAMRIID USAMRIID’s mission is to provide leading edge medical capabilities to deter and defend against current and emerging biological threat agents. Research conducted at USAMRIID leads to medical solutions— vaccines, drugs, diagnostics, and information—that benefit both military personnel and civilians. The Institute plays a key role as a lead military medical research laboratory for lethal viruses for the Military Infectious Disease Research Program, and for the Defense Threat Reduction Agency’s Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command. For more information, visit www.usamriid.army.mil . No commercial endorsement is implied. ###
